Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study-Reference-Cited by-同舟云学术

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study

Published:2024-09 Issue:9 Volume:25 Page:1188-1201
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Karpinski Madeleine J,Hüsing Johannes,Claassen Kevin,Möller Lennart,Kajüter Hiltraud,Oesterling Florian,Grünwald Viktor,Umutlu Lale,Kleesiek Jens,Telli Tugce,Merkel-Jens Anja,Hüsing Anika,Kesch Claudia,Herrmann Ken,Eiber Matthias,Hoberück Sebastian,Meyer Philipp T,Kind Felix,Rahbar Kambiz,Schäfers Michael,Stang Andreas,Hadaschik Boris A,Fendler Wolfgang P

Funder

North Rhine-Westphalia State Ministry of Innovation Science Research and Technology

Publisher

Elsevier BV

Reference30 articles.

1. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging;Eder;Bioconjug Chem,2012

2. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial;Fendler;JAMA Oncol,2019

3. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer;Fendler;Clin Cancer Res,2019

4. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study;Hofman;Lancet,2020

5. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis;Perera;Eur Urol,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer;The Lancet Oncology;2024-09